APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monogenic Disease Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Monogenic Disease Testing Market Outlook and Growth Opportunities 2026

16 January 2026191 pages

Choose your research edition.

Industry ResearchMonogenic Disease Testing Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Monogenic Disease Testing Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Monogenic Disease Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monogenic Disease Testing Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Monogenic Disease Testing Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Monogenic Disease Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Monogenic Disease Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Monogenic Disease Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monogenic Disease Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Monogenic Disease Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Monogenic Disease Testing market include Celera Support Services, Abbott, ELITech Group, Auto Genomics, PerkinElmer and Bio-Rad Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Monogenic Disease Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Monogenic Disease Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Monogenic Disease Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Monogenic Disease Testing market.

Monogenic Disease Testing Segment by Company

Celera Support Services

Abbott

ELITech Group

Auto Genomics

PerkinElmer

Bio-Rad Laboratories

Monogenic Disease Testing Segment by Type

Carrier Testing

Diagnostic Testing

New-Born Screening

Predictive and Pre-Symptomatic Testing

Prenatal Testing

Monogenic Disease Testing Segment by Application

Hospitals

Clinics

Others

Monogenic Disease Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Monogenic Disease Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Monogenic Disease Testing key companies, revenue, market share, and recent developments.

3. To split the Monogenic Disease Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Monogenic Disease Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Monogenic Disease Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Monogenic Disease Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monogenic Disease Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monogenic Disease Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monogenic Disease Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Monogenic Disease Testing industry.

Chapter 3: Detailed analysis of Monogenic Disease Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Monogenic Disease Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Monogenic Disease Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Monogenic Disease Testing Industry Trends Table 2. Monogenic Disease Testing Industry Drivers Table 3. Monogenic Disease Testing Industry Opportunities and Challenges Table 4. Monogenic Disease Testing Industry Restraints Table 5. Global Monogenic Disease Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Monogenic Disease Testing Revenue Share by Company (2021-2026) Table 7. Global Monogenic Disease Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Monogenic Disease Testing Key Company Manufacturing Base & Headquarters Table 9. Global Monogenic Disease Testing Company, Product Type & Application Table 10. Global Monogenic Disease Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Monogenic Disease Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Carrier Testing Table 15. Significant Companies of Diagnostic Testing Table 16. Significant Companies of New-Born Screening Table 17. Significant Companies of Predictive and Pre-Symptomatic Testing Table 18. Significant Companies of Prenatal Testing Table 19. Global Monogenic Disease Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Monogenic Disease Testing Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Monogenic Disease Testing Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Monogenic Disease Testing Sales Value Share by Type (2021-2026) Table 23. Global Monogenic Disease Testing Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Clinics Table 26. Significant Companies of Others Table 27. Global Monogenic Disease Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Monogenic Disease Testing Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Monogenic Disease Testing Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Monogenic Disease Testing Sales Value Share by Application (2021-2026) Table 31. Global Monogenic Disease Testing Sales Value Share by Application (2027-2032) Table 32. Global Monogenic Disease Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Monogenic Disease Testing Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Monogenic Disease Testing Sales Value Share by Region (2021-2026) Table 35. Global Monogenic Disease Testing Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Monogenic Disease Testing Sales Value Share by Region (2027-2032) Table 37. Global Monogenic Disease Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Monogenic Disease Testing Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Monogenic Disease Testing Sales Value Market Share by Country (2021-2026) Table 40. Global Monogenic Disease Testing Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Monogenic Disease Testing Sales Value Market Share by Country (2027-2032) Table 42. Celera Support Services Company Information Table 43. Celera Support Services Business Overview Table 44. Celera Support Services Monogenic Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Celera Support Services Monogenic Disease Testing Product Portfolio Table 46. Celera Support Services Recent Development Table 47. Abbott Company Information Table 48. Abbott Business Overview Table 49. Abbott Monogenic Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Abbott Monogenic Disease Testing Product Portfolio Table 51. Abbott Recent Development Table 52. ELITech Group Company Information Table 53. ELITech Group Business Overview Table 54. ELITech Group Monogenic Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. ELITech Group Monogenic Disease Testing Product Portfolio Table 56. ELITech Group Recent Development Table 57. Auto Genomics Company Information Table 58. Auto Genomics Business Overview Table 59. Auto Genomics Monogenic Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Auto Genomics Monogenic Disease Testing Product Portfolio Table 61. Auto Genomics Recent Development Table 62. PerkinElmer Company Information Table 63. PerkinElmer Business Overview Table 64. PerkinElmer Monogenic Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. PerkinElmer Monogenic Disease Testing Product Portfolio Table 66. PerkinElmer Recent Development Table 67. Bio-Rad Laboratories Company Information Table 68. Bio-Rad Laboratories Business Overview Table 69. Bio-Rad Laboratories Monogenic Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Bio-Rad Laboratories Monogenic Disease Testing Product Portfolio Table 71. Bio-Rad Laboratories Recent Development Table 72. Research Programs/Design for This Report Table 73. Authors List of This Report Table 74. Secondary Sources Table 75. Primary Sources List of Figures Figure 1. Monogenic Disease Testing Product Image Figure 2. Global Monogenic Disease Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monogenic Disease Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Monogenic Disease Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Carrier Testing Image Figure 8. Diagnostic Testing Image Figure 9. New-Born Screening Image Figure 10. Predictive and Pre-Symptomatic Testing Image Figure 11. Prenatal Testing Image Figure 12. Global Monogenic Disease Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Monogenic Disease Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Monogenic Disease Testing Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Clinics Image Figure 17. Others Image Figure 18. Global Monogenic Disease Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Monogenic Disease Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Monogenic Disease Testing Sales Value Share by Application (2021-2032) Figure 21. Global Monogenic Disease Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Monogenic Disease Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Monogenic Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 24. North America Monogenic Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Monogenic Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Monogenic Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Monogenic Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Monogenic Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Monogenic Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 30. South America Monogenic Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Monogenic Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Monogenic Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Monogenic Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Carrier Testing
  • Diagnostic Testing
  • New-Born Screening
  • Predictive and Pre-Symptomatic Testing
  • Prenatal Testing
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Celera Support Services
  • Abbott
  • ELITech Group
  • Auto Genomics
  • PerkinElmer
  • Bio-Rad Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Monogenic Disease Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Monogenic Disease Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Monogenic Disease Testing Market Dynamics
  1. 2.1 Monogenic Disease Testing Industry Trends
  2. 2.2 Monogenic Disease Testing Industry Drivers
  3. 2.3 Monogenic Disease Testing Industry Opportunities and Challenges
  4. 2.4 Monogenic Disease Testing Industry Restraints
3 Monogenic Disease Testing Market by Company
  1. 3.1 Global Monogenic Disease Testing Company Revenue Ranking in 2025
  2. 3.2 Global Monogenic Disease Testing Revenue by Company (2021-2026)
  3. 3.3 Global Monogenic Disease Testing Company Ranking (2024-2026)
  4. 3.4 Global Monogenic Disease Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Monogenic Disease Testing Company Product Type and Application
  6. 3.6 Global Monogenic Disease Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Monogenic Disease Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Monogenic Disease Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Monogenic Disease Testing Market by Type
  1. 4.1 Monogenic Disease Testing Type Introduction
  2. 4.1.1 Carrier Testing
  3. 4.1.2 Diagnostic Testing
  4. 4.1.3 New-Born Screening
  5. 4.1.4 Predictive and Pre-Symptomatic Testing
  6. 4.1.5 Prenatal Testing
  7. 4.2 Global Monogenic Disease Testing Sales Value by Type
  8. 4.2.1 Global Monogenic Disease Testing Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Monogenic Disease Testing Sales Value by Type (2021-2032)
  10. 4.2.3 Global Monogenic Disease Testing Sales Value Share by Type (2021-2032)
5 Monogenic Disease Testing Market by Application
  1. 5.1 Monogenic Disease Testing Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Monogenic Disease Testing Sales Value by Application
  6. 5.2.1 Global Monogenic Disease Testing Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Monogenic Disease Testing Sales Value by Application (2021-2032)
  8. 5.2.3 Global Monogenic Disease Testing Sales Value Share by Application (2021-2032)
6 Monogenic Disease Testing Regional Value Analysis
  1. 6.1 Global Monogenic Disease Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Monogenic Disease Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Monogenic Disease Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Monogenic Disease Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Monogenic Disease Testing Sales Value (2021-2032)
  7. 6.3.2 North America Monogenic Disease Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Monogenic Disease Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Monogenic Disease Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Monogenic Disease Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Monogenic Disease Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Monogenic Disease Testing Sales Value (2021-2032)
  16. 6.6.2 South America Monogenic Disease Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Monogenic Disease Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Monogenic Disease Testing Sales Value Share by Country, 2025 VS 2032
7 Monogenic Disease Testing Country-level Value Analysis
  1. 7.1 Global Monogenic Disease Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Monogenic Disease Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Monogenic Disease Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Monogenic Disease Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Monogenic Disease Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Monogenic Disease Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Monogenic Disease Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Celera Support Services
  2. 8.1.1 Celera Support Services Company Information
  3. 8.1.2 Celera Support Services Business Overview
  4. 8.1.3 Celera Support Services Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Celera Support Services Monogenic Disease Testing Product Portfolio
  6. 8.1.5 Celera Support Services Recent Developments
  7. 8.2 Abbott
  8. 8.2.1 Abbott Company Information
  9. 8.2.2 Abbott Business Overview
  10. 8.2.3 Abbott Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Monogenic Disease Testing Product Portfolio
  12. 8.2.5 Abbott Recent Developments
  13. 8.3 ELITech Group
  14. 8.3.1 ELITech Group Company Information
  15. 8.3.2 ELITech Group Business Overview
  16. 8.3.3 ELITech Group Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ELITech Group Monogenic Disease Testing Product Portfolio
  18. 8.3.5 ELITech Group Recent Developments
  19. 8.4 Auto Genomics
  20. 8.4.1 Auto Genomics Company Information
  21. 8.4.2 Auto Genomics Business Overview
  22. 8.4.3 Auto Genomics Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Auto Genomics Monogenic Disease Testing Product Portfolio
  24. 8.4.5 Auto Genomics Recent Developments
  25. 8.5 PerkinElmer
  26. 8.5.1 PerkinElmer Company Information
  27. 8.5.2 PerkinElmer Business Overview
  28. 8.5.3 PerkinElmer Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 PerkinElmer Monogenic Disease Testing Product Portfolio
  30. 8.5.5 PerkinElmer Recent Developments
  31. 8.6 Bio-Rad Laboratories
  32. 8.6.1 Bio-Rad Laboratories Company Information
  33. 8.6.2 Bio-Rad Laboratories Business Overview
  34. 8.6.3 Bio-Rad Laboratories Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bio-Rad Laboratories Monogenic Disease Testing Product Portfolio
  36. 8.6.5 Bio-Rad Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst